Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | TACR3 | P29371 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321550 | 0.85 | CCR3 (0.49) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL2636547 | 0.82 | MEN1 (0.68) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL25411950 | 0.82 | CYP2C9 (0.48) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL4768507 | 0.82 | MGLL (0.48) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL14834316 | 0.81 | CYP2C9 (0.56) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL4772773 | 0.81 | HTT (0.61) | FAAHMGLLLMNA | |
| SCHEMBL4768774 | 0.81 | CA12 (0.46) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL3026559 | 0.81 | CYP2C9 (0.67) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL4576736 | 0.81 | L3MBTL1 (0.69) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL15840452 | 0.80 | NPC1 (0.67) | CYP2C9CYP2C19MAPK14HTR2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-1219605-B1 | UREA COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-6787650-B1 | CCR5 ANTAGONISTIC ACTIVITY; SUCH AS N-(3-(4-BENZYL-1-PIPERIDINYL)PROPYL)-N'-4-CHLOROPHENYL)-N-PHENYLUREA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1060162-B1 | URETHANES DERIVED FROM AZACYCLOALKANES, THIO AND DITHIO ANALOGUES, PRODUCTION AND USE THEREOF AS 2,3 EPOXYSQUALENE LANESTEROL CYCLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-03-19 | — | — | EP | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| EP-1219605-A1 | UREA COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6339096-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDAEMIAS, HYPERCHOLESTEROLAEMIAS AND ATHEROSCLEROSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-15 | — | — | US | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| EP-1060162-A1 | URETHANES DERIVED FROM AZACYCLOALKANES, THIO AND DITHIO ANALOGUES, PRODUCTION AND USE THEREOF AS 2,3 EPOXYSQUALENE LANESTEROL CYCLASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999029669-A1 | URETHANES DERIVED FROM AZACYCLOALKANES, THIO AND DITHIO ANALOGUES, PRODUCTION AND USE THEREOF AS 2,3 EPOXYSQUALENE LANESTEROL CYCLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | CYP2C9 1111/4885CYP2C19 1576/4885MAPK14 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.